Tarsus Pharmaceuticals, Inc. — Form 8-K/A
Filed October 13, 2026 · analyzed by the 8-K Agent
8-K/A
▲ Likely positive
significance 72/100
What the filing says
On July 31, 2026, Tarsus Pharmaceuticals agreed to acquire private biotech Alkeus Pharmaceuticals for $450M upfront ($270M cash, $180M stock at $83.21/share = 2.77M shares) plus up to $350M in regulatory/sales milestones and low-single-digit royalties on ALK-001 (gildeuretinol) net sales. Alkeus is a pre-revenue R&D-stage company with $109.6M accumulated deficit (as of June 30, 2026), $48.7M cash, and substantial going-concern doubt. The merger closed September 4, 2026; Tarsus also completed a concurrent $125M private placement at $56/share.
Why this rating
Material M&A (~$450M upfront = 26% of Tarsus's $1.7B market cap) adds transformational pipeline asset (clinical-stage ophthalmology program). However, Alkeus is pre-revenue with execution risk; $568M IPR&D expense recognized immediately. Tarsus gains strategic ophthalmology franchise and royalty upside. Positive for revenue diversification; dilutive near-term (stock issuance, IPR&D charge).
Tradability signal
NO TRADE
No trade: positive news with only -1.1% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: +0.14% over 4 hrs, n=78). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $70.82 ▼ 0.30% | at our read · unknown $71.03 | +10 min · unknown $71.47 ▲ 0.61% | +30 min · unknown $72.22 ▲ 1.68% | +1 hr · unknown $72.03 ▲ 1.40% | +4 hrs · unknown $73.07 ▲ 2.86% |
The stock had already moved +0.30% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.